HK
Insider
Helen Susan Kim
DirectorHelen Susan Kim (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Aktis Oncology, Inc. (AKTS). Across 1 priced purchase filing, the average 21-session return was -20.7% from execution and -20.7% from disclosure (delay-adjusted; derived). The largest single filing was $15.0M of AKTS (835,000 sh across 2 lots, as filed), executed Jan 12.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-20.7%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-20.7%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
0d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$15.0M
shares × price, as filed
Last traded
Jan 12
Filed Jan 12
Median ADV $8.9M across their filed names
Open performance→Volume by month
Buys $15.0M
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
AKTSRecent filings
AKTSPURCHASE
Aktis Oncology, Inc.
View filing →
$15.0M835,000 sh across 2 lots
Exec Jan 12
Filed Jan 12 · 5:00 PM ET